Quantitative analysis of lung function and airway remodeling using ventilation/perfusion single photon emission tomography/computed tomography and HRCT in patients with chronic obstructive pulmonary disease and asthma.
Airway remodeling
HRCT
Quantitative analysis
Regional function
Ventilation/perfusion SPECT/CT
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
01
02
2023
accepted:
20
05
2023
medline:
7
8
2023
pubmed:
3
6
2023
entrez:
2
6
2023
Statut:
ppublish
Résumé
To investigate the role of V/P SPECT/CT and HRCT quantitative parameters in evaluating COPD and asthma disease severity, airway obstructivity-grade, ventilation and perfusion distribution patterns, airway remodeling, and lung parenchymal changes. Fifty-three subjects who underwent V/P SPECT/CT, HRCT, and pulmonary function tests (PFTs) were included. Preserved lung ventilation (PLVF), perfusion function (PLPF), airway obstructivity-grade (OG), proportion of anatomical volume, ventilation and perfusion contribution of each lobe, and V/P distribution patterns were evaluated using V/P SPECT/CT. The quantitative parameters of HRCT included CT bronchial and CT pulmonary function parameters. In addition, the correlation and difference of V/P SPECT/CT-, HRCT-, and PFT-related parameters were compared. There was a statistically significant difference between severe asthma and severe-very severe COPD in CT bronchial parameters, like WA, LA and AA, in the lung segment airways (P < 0.05). CT bronchial parameters, like as WT and WA, were statistically significant (p < 0.05) among asthma patients. The EI of severe-very severe COPD was different from that of the disease severity groups in asthma patients (P < 0.05). The airway obstructivity-grade, PLVF and PLPF differed significantly among the severe-very severe COPD and mild-moderate asthma patients (P < 0.05). And the PLPF was statistically significant among the disease severity groups in asthma and COPD (P < 0.05). OG and PLVF, PLPF, and PFT parameters were significantly correlated, with the FEV1 correlation being the most significant (r = - 0.901, r = 0.915, and r = 0.836, respectively; P < 0.01). There was a strong negative correlation between OG and PLVF (r = - 0.945) and OG and PLPF (r = - 0.853) and a strong positive correlation between PLPF and PLVF (r = 0.872). In addition, OG, PLVF, and PLPF were moderately to strongly correlated with CT lung function parameters (r = - 0.673 to - 0.839; P < 0.01), while lowly to moderately correlated with most CT bronchial parameters (r = - 0.366 to - 0.663, P < 0.01). There were three different V/P distribution patterns, including matched, mismatched, and reverse mismatched patterns. Last, the CT volume overestimated the contribution in the upper lobes and underestimated the lower lobes' contribution to overall function. Quantitative assessment of ventilation and perfusion abnormalities and the degree of pulmonary functional loss by V/P SPECT/CT shows promise as an objective measure to assess the severity of disease and lung function to guide localized treatments. There are differences between HRCT parameters and SPECT/CT parameters among the disease severity groups in asthma and COPD, which may enhance, to some extent, the understanding of complex physiological mechanisms in asthma and COPD.
Identifiants
pubmed: 37268867
doi: 10.1007/s12149-023-01848-7
pii: 10.1007/s12149-023-01848-7
doi:
Substances chimiques
periodate-lysine-paraformaldehyde
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
504-516Subventions
Organisme : 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
ID : ZYGD18016
Organisme : "1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
ID : 2021HXFH033
Informations de copyright
© 2023. The Author(s) under exclusive licence to The Japanese Society of Nuclear Medicine.
Références
NICE Evidence Reviews Collection. Evidence reviews for the length of corticosteroid use during exacerbations: Chronic obstructive pulmonary disease in over 16s: diagnosis and management: Evidence review J. London: National Institute for Health and Care Excellence (NICE) Copyright © NICE 2019; 2019.
Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155:179–91.
pubmed: 21810710
doi: 10.7326/0003-4819-155-3-201108020-00008
Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173:Itc17-itc32.
pubmed: 32745458
doi: 10.7326/AITC202008040
Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol. 2009;4:435–59.
pubmed: 18954287
doi: 10.1146/annurev.pathol.4.110807.092145
Lapperre TS, Postma DS, Gosman MM, Snoeck-Stroband JB, ten Hacken NH, Hiemstra PS, et al. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax. 2006;61:115–21.
pubmed: 16055612
doi: 10.1136/thx.2005.040519
Zhou-Suckow Z, Duerr J, Hagner M, Agrawal R, Mall MA. Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell Tissue Res. 2017;367:537–50.
pubmed: 28108847
doi: 10.1007/s00441-016-2562-z
Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–53.
pubmed: 15215480
doi: 10.1056/NEJMoa032158
Su Y, Han W, Kovacs-Kasa A, Verin AD, Kovacs L. HDAC6 activates ERK in airway and pulmonary vascular remodeling of chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2021;65:603–14.
pubmed: 34280336
pmcid: 8641801
doi: 10.1165/rcmb.2020-0520OC
Park SW, Lim MN, Kim WJ, Bak SH. Quantitative assessment the longitudinal changes of pulmonary vascular counts in chronic obstructive pulmonary disease. Respir Res. 2022;23:29.
pubmed: 35164757
pmcid: 8842934
doi: 10.1186/s12931-022-01953-7
Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–76.
pubmed: 11316667
doi: 10.1164/ajrccm.163.5.2101039
Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391:1706–17.
pubmed: 29650248
doi: 10.1016/S0140-6736(18)30841-9
Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391:783–800.
pubmed: 29273246
doi: 10.1016/S0140-6736(17)33311-1
Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15:57–65.
pubmed: 25534623
pmcid: 4390063
doi: 10.1038/nri3786
Kasahara K, Shiba K, Ozawa T, Okuda K, Adachi M. Correlation between the bronchial subepithelial layer and whole airway wall thickness in patients with asthma. Thorax. 2002;57:242–6.
pubmed: 11867829
pmcid: 1746264
doi: 10.1136/thorax.57.3.242
Song WJ, Kang MG, Chang YS, Cho SH. Epidemiology of adult asthma in Asia: toward a better understanding. Asia Pac Allergy. 2014;4:75–85.
pubmed: 24809012
pmcid: 4005350
doi: 10.5415/apallergy.2014.4.2.75
Koster TD, Klooster K, Ten Hacken NHT, van Dijk M, Slebos DJ. Endobronchial valve therapy for severe emphysema: an overview of valve-related complications and its management. Expert Rev Respir Med. 2020;14:1235–47.
pubmed: 32842819
doi: 10.1080/17476348.2020.1813571
Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.
pubmed: 22878278
doi: 10.1164/rccm.201204-0596PP
Battaglia S, den Hertog H, Timmers MC, Lazeroms SP, Vignola AM, Rabe KF, et al. Small airways function and molecular markers in exhaled air in mild asthma. Thorax. 2005;60:639–44.
pubmed: 16061704
pmcid: 1747499
doi: 10.1136/thx.2004.035279
Nuttall AGL, Velásquez W, Beardsmore CS, Gaillard EA. Lung clearance index: assessment and utility in children with asthma. Eur Respir Rev. 2019;28: 190046.
pubmed: 31748419
pmcid: 9488960
doi: 10.1183/16000617.0046-2019
Şerifoğlu İ, Ulubay G. The methods other than spirometry in the early diagnosis of COPD. Tuberk Toraks. 2019;67:63–70.
pubmed: 31130137
doi: 10.5578/tt.68162
Jarenbäck L, Ankerst J, Bjermer L, Tufvesson E. Flow-volume parameters in COPD related to extended measurements of lung volume, diffusion, and resistance. Pulm Med. 2013;2013: 782052.
pubmed: 23844288
pmcid: 3697409
doi: 10.1155/2013/782052
Bajc M, Markstad H, Jarenbäck L, Tufvesson E, Bjermer L, Jögi J. Grading obstructive lung disease using tomographic pulmonary scintigraphy in patients with chronic obstructive pulmonary disease (COPD) and long-term smokers. Ann Nucl Med. 2015;29:91–9.
pubmed: 25315109
doi: 10.1007/s12149-014-0913-y
Satoh K, Nakano S, Tanabe M, Nishiyama Y, Takahashi K, Kobayashi T, et al. A clinical comparison between Technegas SPECT, CT, and pulmonary function tests in patients with emphysema. Radiat Med. 1997;15:277–82.
pubmed: 9445149
Jögi J, Ekberg M, Jonson B, Bozovic G, Bajc M. Ventilation/perfusion SPECT in chronic obstructive pulmonary disease: an evaluation by reference to symptoms, spirometric lung function and emphysema, as assessed with HRCT. Eur J Nucl Med Mol Imaging. 2011;38:1344–52.
pubmed: 21365251
doi: 10.1007/s00259-011-1757-5
Qin S, Yu X, Ma Q, Lin L, Li Q, Liu H, et al. Quantitative CT analysis of small airway remodeling in patients with chronic obstructive pulmonary disease by a new image post-processing system. Int J Chron Obstruct Pulmon Dis. 2021;16:535–44.
pubmed: 33688178
pmcid: 7936712
doi: 10.2147/COPD.S295320
Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An Official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med. 2019;200:e70–88.
pubmed: 31613151
pmcid: 6794117
doi: 10.1164/rccm.201908-1590ST
Bajc M, Schümichen C, Grüning T, Lindqvist A, Le Roux PY, Alatri A, et al. EANM guideline for ventilation/perfusion single-photon emission computed tomography (SPECT) for diagnosis of pulmonary embolism and beyond. Eur J Nucl Med Mol Imaging. 2019;46:2429–51.
pubmed: 31410539
pmcid: 6813289
doi: 10.1007/s00259-019-04450-0
Jögi J, Jonson B, Ekberg M, Bajc M. Ventilation-perfusion SPECT with 99mTc-DTPA versus Technegas: a head-to-head study in obstructive and nonobstructive disease. J Nucl Med. 2010;51:735–41.
pubmed: 20395338
doi: 10.2967/jnumed.109.073957
Bajc M, Olsson CG, Olsson B, Palmer J, Jonson B. Diagnostic evaluation of planar and tomographic ventilation/perfusion lung images in patients with suspected pulmonary emboli. Clin Physiol Funct Imaging. 2004;24:249–56.
pubmed: 15383080
doi: 10.1111/j.1475-097X.2004.00546.x
Bajc M, Chen Y, Wang J, Li XY, Shen WM, Wang CZ, et al. Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease. Int J Chron Obstruct Pulmon Dis. 2017;12:1579–87.
pubmed: 28603413
pmcid: 5457181
doi: 10.2147/COPD.S131847
Battaglia S, Mauad T, van Schadewijk AM, Vignola AM, Rabe KF, Bellia V, et al. Differential distribution of inflammatory cells in large and small airways in smokers. J Clin Pathol. 2007;60:907–11.
pubmed: 16917001
doi: 10.1136/jcp.2006.037002
Hasegawa M, Nasuhara Y, Onodera Y, Makita H, Nagai K, Fuke S, et al. Airflow limitation and airway dimensions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:1309–15.
pubmed: 16556695
doi: 10.1164/rccm.200601-037OC
Nakano Y, Müller NL, King GG, Niimi A, Kalloger SE, Mishima M, et al. Quantitative assessment of airway remodeling using high-resolution CT. Chest. 2002;122:271s-s275.
pubmed: 12475796
doi: 10.1378/chest.122.6_suppl.271S
Pillai RA, Calhoun WJ. Introduction to asthma and phenotyping. Adv Exp Med Biol. 2014;795:5–15.
pubmed: 24162899
doi: 10.1007/978-1-4614-8603-9_1
Davidson W, Bai TR. Lung structural changes in chronic obstructive pulmonary diseases. Curr Drug Targets Inflamm Allergy. 2005;4:643–9.
pubmed: 17305520
doi: 10.2174/156801005774912842
Sandek K, Bratel T, Lagerstrand L, Rosell H. Relationship between lung function, ventilation-perfusion inequality and extent of emphysema as assessed by high-resolution computed tomography. Respir Med. 2002;96:934–43.
pubmed: 12418592
doi: 10.1053/rmed.2002.1371
Masiero PR, Menna-Barreto SS, Moreira MA, Mosmann MP, Mayer CM, Spiro BL. Perfused lung volume to thoracic gas volume ratio (perfused lung fraction) in patients with COPD and in controls. Nucl Med Commun. 2011;32:530–4.
pubmed: 21519305
doi: 10.1097/MNM.0b013e32834207cb
Bailey DL, Farrow CE, Lau EM. V/Q SPECT-normal values for lobar function and comparison with CT volumes. Semin Nucl Med. 2019;49:58–61.
pubmed: 30545518
doi: 10.1053/j.semnuclmed.2018.10.008
Wechalekar K, Garner J, Gregg S. Pre-surgical evaluation of lung function. Semin Nucl Med. 2019;49:22–30.
pubmed: 30545513
doi: 10.1053/j.semnuclmed.2018.10.011
Kristiansen JF, Perch M, Iversen M, Krakauer M, Mortensen J. Lobar Quantification by Ventilation/Perfusion SPECT/CT in Patients with Severe Emphysema Undergoing Lung Volume Reduction with Endobronchial Valves. Respiration. 2019;98:230–8.
pubmed: 31167210
doi: 10.1159/000500407
McDonald VM, Urroz PD, Bajc M, Rutherford N, Brooker B, Gibson PG. Imaging for precision medicine: can V-P SPECT measure mepolizumab response in asthma? Respirol Case Rep. 2021;9: e00717.
pubmed: 33552524
pmcid: 7848709
doi: 10.1002/rcr2.717
Weissmann N. Chronic obstructive pulmonary disease and pulmonary vascular disease. A comorbidity? Ann Am Thorac Soc. 2018;15:S278–81.
pubmed: 30759003
pmcid: 6944394
doi: 10.1513/AnnalsATS.201808-532MG
Frizzelli R, Lettieri C, Caiola S, Maulucci L, Pinzi C, Agostini F, et al. Unexplained hypoxemia in COPD with cardiac shunt. Respir Med Case Rep. 2022;37: 101661.
pubmed: 35585906
pmcid: 9108509
Amen EM, Becker EM, Truebel H. Analysis of V/Q-matching—a safety “biomarker” in pulmonary drug development? Biomarkers. 2011;16(Suppl 1):S5-10.
pubmed: 21707444
doi: 10.3109/1354750X.2011.585243